NANOBIOTIX (NANO.PA) Stock Price & Overview
EPA:NANO • FR0011341205
Current stock price
The current stock price of NANO.PA is 26.5 EUR. Today NANO.PA is down by -2.03%. In the past month the price increased by 2.71%. In the past year, price increased by 672.15%.
NANO.PA Key Statistics
- Market Cap
- 1.282B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.09
- Dividend Yield
- N/A
NANO.PA Stock Performance
NANO.PA Stock Chart
NANO.PA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to NANO.PA. When comparing the yearly performance of all stocks, NANO.PA is one of the better performing stocks in the market, outperforming 99.8% of all stocks.
NANO.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NANO.PA. Both the profitability and financial health of NANO.PA have multiple concerns.
NANO.PA Earnings
On November 24, 2025 NANO.PA reported an EPS of -0.11 and a revenue of 26.64M. The company beat EPS expectations (65.21% surprise) and beat revenue expectations (33.24% surprise).
NANO.PA Forecast & Estimates
12 analysts have analysed NANO.PA and the average price target is 23.32 EUR. This implies a price decrease of -11.98% is expected in the next year compared to the current price of 26.5.
For the next year, analysts expect an EPS growth of 78.75% and a revenue growth 103.37% for NANO.PA
NANO.PA Groups
Sector & Classification
NANO.PA Financial Highlights
Over the last trailing twelve months NANO.PA reported a non-GAAP Earnings per Share(EPS) of -1.09. The EPS decreased by -47.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -114.32% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NANO.PA Ownership
NANO.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 25.12 | 37.241B | ||
| 1AE | ARGENX SE | 25.1 | 37.241B | ||
| 22UA | BIONTECH SE-ADR | N/A | 18.407B | ||
| 2X1 | ABIVAX SA | N/A | 7.512B | ||
| ABVX | ABIVAX SA | N/A | 7.496B | ||
| GLPG | GALAPAGOS NV | N/A | 1.741B | ||
| GXE | GALAPAGOS NV | N/A | 1.74B | ||
| 6IV | INVENTIVA SA | N/A | 1.094B | ||
| IVA | INVENTIVA SA | N/A | 1.069B | ||
| PHIL | PHILOGEN SPA | 18.09 | 657.9M | ||
| GNFT | GENFIT | 815.2 | 425.025M | ||
| FYB | FORMYCON AG | N/A | 314.879M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About NANO.PA
Company Profile
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 103 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Company Info
IPO: 2012-10-29
NANOBIOTIX
60 rue de Wattignies
Paris ILE-DE-FRANCE FR
Employees: 108
Phone: 33140260470
NANOBIOTIX / NANO.PA FAQ
What does NANO do?
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 103 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
What is the current price of NANO stock?
The current stock price of NANO.PA is 26.5 EUR. The price decreased by -2.03% in the last trading session.
Does NANO stock pay dividends?
NANO.PA does not pay a dividend.
What is the ChartMill rating of NANOBIOTIX stock?
NANO.PA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is NANO.PA stock listed?
NANO.PA stock is listed on the Euronext Paris exchange.
What is the expected growth for NANO stock?
The Revenue of NANOBIOTIX (NANO.PA) is expected to grow by 103.37% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for NANOBIOTIX?
NANOBIOTIX (NANO.PA) currently has 108 employees.